Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Dec 21;3(11):e967147.
doi: 10.4161/21624011.2014.967147. eCollection 2014 Nov.

Novel immune checkpoint blocker approved for the treatment of advanced melanoma

Lorenzo Galluzzi  1 , Guido Kroemer  2 , Alexander Eggermont  3
Affiliations

Novel immune checkpoint blocker approved for the treatment of advanced melanoma

Lorenzo Galluzzi et al. Oncoimmunology. .
No abstract available

Keywords: CTLA4; CTLA4, cytotoxic T lymphocyte-associate protein 4; FDA, Food and Drug Administration; Keytruda™; PD-1; PDCD1/PD-1, programmed cell death 1; Yervoy™; ipilimumab; nivolumab.

PubMed Disclaimer

References

    1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:; http://dx.doi.org/ 10.1038/nrc3239 - DOI - PMC - PubMed
    1. Aranda F, Vacchelli E, Eggermont A, Galon J, Fridman WH, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014; 3:e27297; PMID:; http://dx.doi.org/ 10.4161/onci.27297 - DOI - PMC - PubMed
    1. Chawla A, Philips AV, Alatrash G, Mittendorf E. Immune checkpoints: a therapeutic target in triple negative breast cancer. Oncoimmunology 2014; 3:e28325; PMID:; http://dx.doi.org/ 10.4161/onci.28325 - DOI - PMC - PubMed
    1. Brahmer JR. Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer? Semin Oncol 2014; 41:126-32; PMID:; http://dx.doi.org/ 10.1053/j.seminoncol.2013.12.014 - DOI - PMC - PubMed
    1. Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer–preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol 2010; 37:430-9; PMID:; http://dx.doi.org/ 10.1053/j.seminoncol.2010.09.005 - DOI - PubMed